Flexible Work
AARP Skills Builder
Flexible Work
ON-DEMAND WEBINARS
Drug Prices
Social Security
Medicare & Medicaid
Caregiving
LONG-TERM CARE
State Guides
Prepare to Care Guides
End of Life
Home Technology
Get Happier
POSSIBILITIES OF AI
Relationships
Home Health
Leaving AARP.org Website
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
BrandAmp by AARP provides the opportunity for our highly vetted marketing partners to share their expert knowledge, insights and storytelling with loyal and engaged readers like you. Each piece of paid content is created in collaboration with the disclosed advertiser and AARP Media Sales’ content development team.
BrandAmp by AARP content is designed to uphold AARP standards of excellence and inspire conversation. Only advertisers who have gone through the strictest reviews are cleared to bring their message directly to members using all of AARP media properties (AARP.org, social media, email newsletters and our print publications). Our pledge to members is work with brands whose products and services are of value to the 50+ audience; and are committed to the type of compelling, informative, entertaining and useful content members are accustomed to seeing within AARP media properties.
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
The Food and Drug Administration has seized “thousands of doses” of counterfeit Ozempic doses and is warning consumers that it comes from legitimate drug supply chain sources.
Five individuals have experienced illness, although none have developed serious conditions. The symptoms observed align with the known side effects of Ozempic.
Retailers, health care practitioners and patients are asked to verify the authenticity of their semaglutide products as the agency continues to investigate the matter.
The FDA recommended that pharmacies only purchase Ozempic through authorized distributors of Novo Nordisk, the drug manufacturer. Products should also be reviewed with the accompanying photographs to verify their legitimacy.
Both the FDA and Novo Nordisk are testing the seized products and do not have information about their identity, quality or safety.
However, the they determined that the needles in the products were fake, putting the sterility of the needles in doubt. The products’ pen label, accompanying patient information and carton were also identified as counterfeit.
Meanwhile, patients should not use any products labeled with lot number NAR0074 and serial number 430834149057.
Any business that sells counterfeit or tampered medications can be reported to the FDA by calling the local consumer complaint coordinator or by anonymously filing a suspected criminal activity report.
Novo Nordisk customer care can be reached at 800-727-6500 to address additional questions or concerns.
More From AARP
Risks and Rewards of Weight Loss Medications
What to know about the drugs and their possible side effectsWhat to Know About Weight-Loss Drugs
Medications could have a big impact on the obesity epidemic